Transdermal Delivery of Ondansetron Hydrochloride via Bilosomal Systems: In Vitro, Ex Vivo, and In Vivo Characterization Studies
View/ Open
Date
2018Author
Ammar, Hussein O.
Mohamed, Magdy Ibrahim
Tadros, 2 Mina Ibrahim
Fouly, Aya Adel
Metadata
Show full item recordAbstract
Ondansetron hydrochloride (OND) is commonly used for management of
postoperative and chemotherapeutic-induced nausea and vomiting. It suffers from low
bioavailability (60%) and rapid elimination (t1/2; 3–4 h). The current work aimed to develop
OND-loaded bilosomes as a promising transdermal delivery system capable of surmount
drug limitations. The variables influencing the development of OND-loaded bilosomes and
niosomes (18 systems) via the thin film hydration technique were investigated, including
surfactant type (Span®60 or Span®80), surfactant/cholesterol molar ratio (7:0, 7:1, or 7:3),
and sodium deoxycholate (SDC) concentration (0, 2.5, or 5%, w/v). The systems were
characterized for particle size, polydispersity index, zeta potential, drug entrapment efficiency
(EE%), and in vitro permeation. Based on factorial analysis (32
·21
) and calculations of
desirability values, six systems were further subjected to ex vivo permeation through excised
rat skin, differential scanning calorimetry (DSC), powder x-ray diffraction (PXRD), and
transmission electron microscopy. Histopathological and in vivo permeation studies in rats
were conducted on the best achieved system (B6) in comparison to drug solution. Higher
desirability values were achieved with Span® 60-based bilosomes, surfactant/cholesterol
molar ratio of 7:1, and SDC concentration of 2.5% w/v with respect to small vesicle size,
polydispersity index and high zeta potential, EE%, and cumulative drug permeation. OND
was dispersed in amorphous state as revealed from DSC and PXRD studies. No marked
effect was observed in rat skin following application of B6 system while higher ex vivo and
in vivo cumulative permeation profiles were revealed. Bilosomal systems were considered as
safe and efficient carriers for the transdermal delivery for OND.
Collections
- Articles [227]